Vanta Bioscience（540729）株式概要ヴァンタ・バイオサイエンス社は、その子会社とともにインドで前臨床試験受託機関として活動している。 詳細540729 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績3/6財務の健全性1/6配当金0/6報酬今年は黒字化を達成 リスク分析利払いは収益で十分にカバーされない 意味のある時価総額がありません ( ₹152M )収益が 100 万ドル未満 ( ₹18M )すべてのリスクチェックを見る540729 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW497,212 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG497,212 investors already sharing narrativesYour Fair Value₹Current Price₹25.291.5k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-65m141m2016201920222025202620282031Revenue ₹3.4mEarnings ₹202.2kAdvancedSet Fair ValueView all narrativesVanta Bioscience Limited 競合他社BilcareSymbol: BSE:526853Market cap: ₹1.4bJeevan Scientific TechnologySymbol: BSE:538837Market cap: ₹1.3bBrooks LaboratoriesSymbol: NSEI:BROOKSMarket cap: ₹2.3bInflux HealthtechSymbol: NSEI:INFLUXMarket cap: ₹7.0b価格と性能株価の高値、安値、推移の概要Vanta Bioscience過去の株価現在の株価₹25.2952週高値₹31.3352週安値₹14.71ベータ1.021ヶ月の変化14.85%3ヶ月変化66.38%1年変化n/a3年間の変化-39.79%5年間の変化-82.69%IPOからの変化-49.62%最新ニュースBoard Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Kartini Hj Abdul Manaf was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹0.15 (vs ₹7.57 loss in FY 2025)Full year 2026 results: EPS: ₹0.15 (up from ₹7.57 loss in FY 2025). Revenue: ₹19.8m (flat on FY 2025). Net income: ₹1.08m (up ₹48.8m from FY 2025). Profit margin: 5.5% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • May 26Vanta Bioscience Limited to Report Second Half, 2026 Results on May 30, 2026Vanta Bioscience Limited announced that they will report second half, 2026 results on May 30, 2026お知らせ • Nov 08Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025お知らせ • Sep 09Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad IndiaReported Earnings • Aug 02Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024)Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.最新情報をもっと見るRecent updatesBoard Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Kartini Hj Abdul Manaf was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹0.15 (vs ₹7.57 loss in FY 2025)Full year 2026 results: EPS: ₹0.15 (up from ₹7.57 loss in FY 2025). Revenue: ₹19.8m (flat on FY 2025). Net income: ₹1.08m (up ₹48.8m from FY 2025). Profit margin: 5.5% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • May 26Vanta Bioscience Limited to Report Second Half, 2026 Results on May 30, 2026Vanta Bioscience Limited announced that they will report second half, 2026 results on May 30, 2026お知らせ • Nov 08Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025お知らせ • Sep 09Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad IndiaReported Earnings • Aug 02Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024)Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 16Vanta Bioscience Limited to Report Second Half, 2025 Results on Jul 19, 2025Vanta Bioscience Limited announced that they will report second half, 2025 results on Jul 19, 2025New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$536k). Market cap is less than US$10m (₹156.5m market cap, or US$1.83m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change).お知らせ • May 21Vanta Bioscience Limited to Report Q4, 2025 Results on May 30, 2025Vanta Bioscience Limited announced that they will report Q4, 2025 results on May 30, 2025New Risk • May 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹153.6m market cap, or US$1.80m).New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹152.8m market cap, or US$1.79m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).New Risk • Nov 16New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹46m (US$543k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$543k). Market cap is less than US$10m (₹259.9m market cap, or US$3.08m).お知らせ • Nov 12Vanta Bioscience Limited to Report First Half, 2025 Results on Nov 14, 2024Vanta Bioscience Limited announced that they will report first half, 2025 results on Nov 14, 2024お知らせ • Sep 13Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad IndiaNew Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹7.2m free cash flow). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 70% per year over the past 5 years. Market cap is less than US$10m (₹351.9m market cap, or US$4.19m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m).Reported Earnings • Jul 25Full year 2024 earnings released: ₹3.67 loss per share (vs ₹10.27 loss in FY 2023)Full year 2024 results: ₹3.67 loss per share (improved from ₹10.27 loss in FY 2023). Revenue: ₹98.3m (up 43% from FY 2023). Net loss: ₹23.2m (loss narrowed 64% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.お知らせ • Jul 11Vanta Bioscience Limited to Report Second Half, 2024 Results on Jul 17, 2024Vanta Bioscience Limited announced that they will report second half, 2024 results on Jul 17, 2024New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹83m free cash flow). Earnings have declined by 76% per year over the past 5 years. Market cap is less than US$10m (₹360.0m market cap, or US$4.32m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₹103m revenue, or US$1.2m).Board Change • Feb 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 12Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance.お知らせ • Sep 07Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony Sikh Village, Bowenpally, Secunderabad 500009 Telangana Andhra Pradesh IndiaBoard Change • Sep 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 12New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹70m (US$839k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Revenue is less than US$1m (₹70m revenue, or US$839k). Market cap is less than US$10m (₹371.1m market cap, or US$4.47m).Reported Earnings • Aug 11Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.お知らせ • Aug 05Vanta Bioscience Limited to Report Second Half, 2023 Results on Aug 10, 2023Vanta Bioscience Limited announced that they will report second half, 2023 results on Aug 10, 2023お知らせ • Jul 12Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that Ms. Vidisha Rathod has resigned as Company Secretary and Compliance Officer of the Company with immediate effect July 10, 2023, due to her pre-occupations and personal reasons. The Company is in the process of appointing a new Company Secretary. In the interim, Mr. Dopesh Raja Mulakala, Managing Director is being appointed as the Compliance officer of the Company.お知らせ • May 23Vanta Bioscience Limited to Report Q4, 2023 Results on May 30, 2023Vanta Bioscience Limited announced that they will report Q4, 2023 results on May 30, 2023お知らせ • Dec 08Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022, at 10:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad 500009 Telangana IndiaBoard Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 16Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that the company has appointed Ms. Vidisha Rathod as company secretary and compliance officer of the company, effective September 15, 2022. Ms. Vidisha Rathod is a qualified company secretary and an associate member of ICSI. She has over 5+ years of rich experience in Secretarial matters. She has previously worked as company secretary with Public Limited Companies like Chrysalis Finance Ltd., Mimanshu Industries Ltd. and Aatash Norcontrol Limited. She has exposure of handling various secretarial and legal matters. She is being appointed as CS and Compliance Officer, effective September 15, 2022 due to the resignation of existing CS. She is not associated with any of the Directors or KMPs of the company.お知らせ • Sep 04Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance OfficerVanta Bioscience Limited announced the resignation of Mr. Zoheb S Sayani as the Company Secretary and Compliance officer of the Company w.e.f.15.09.2022 due to his pre-occupations.Board Change • Jul 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Jun 28Insider recently bought ₹518k worth of stockOn the 21st of June, Chandra Shekar Simhadri bought around 5k shares on-market at roughly ₹98.64 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Jun 03Full year 2022 earnings released: EPS: ₹0.14 (vs ₹0.71 in FY 2021)Full year 2022 results: EPS: ₹0.14 (down from ₹0.71 in FY 2021). Revenue: ₹101.1m (flat on FY 2021). Net income: ₹882.0k (down 80% from FY 2021). Profit margin: 0.9% (down from 4.5% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹0.71 (vs ₹1.59 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹100.4m (down 29% from FY 2020). Net income: ₹4.50m (down 55% from FY 2020). Profit margin: 4.5% (down from 7.1% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 28% per year.Is New 90 Day High Low • Mar 03New 90-day high: ₹150The company is up 7.0% from its price of ₹140 on 03 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 3.0% over the same period.お知らせ • Jan 06Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as DirectorVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the Whole Time Director of the company with effect from the close of working hours of January 4, 2021.お知らせ • Jan 05Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as CEOVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the CEO of the company with effect from the close of working hours of January 04, 2021.Is New 90 Day High Low • Dec 28New 90-day low: ₹124The company is down 31% from its price of ₹180 on 28 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 09New 90-day low: ₹134The company is down 18% from its price of ₹164 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 19% over the same period.お知らせ • Nov 14Vanta Bioscience Limited Enters into Commercial Agreement with One of the Leading German Testing AgencyVanta Bioscience Limited announced that it has entered into a commercial agreement with one of the leading German Testing agency, wherein the Client has commissioned Vanta Bio to carry out Laboratory Testing Services in Biocompatibility and Analytics. The said agreement is valid for a period of 2 years. This is a major break through for the Company considering its decision to foray into Medical Devices vertical. This is not only an acknowledgement of the technical capabilities of Vanta Bio, but also validation of the world class services being provided by the Company. Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition. Expected to generate a revenue of INR 100 million-INR 150 million approx. over the period of 2 years.Is New 90 Day High Low • Nov 04New 90-day low: ₹148The company is down 6.0% from its price of ₹157 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.Is New 90 Day High Low • Sep 23New 90-day high: ₹170The company is up 32% from its price of ₹129 on 25 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 37% over the same period.お知らせ • Jun 20Vanta Bioscience Limited to Report Fiscal Year 2020 Results on Jun 30, 2020Vanta Bioscience Limited announced that they will report fiscal year 2020 results on Jun 30, 2020株主還元540729IN Life SciencesIN 市場7D5.0%1.9%1.0%1Yn/a-1.9%-1.4%株主還元を見る業界別リターン: 540729がIndian Life Sciences業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 540729 Indian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 540729's price volatile compared to industry and market?540729 volatility540729 Average Weekly Movementn/aLife Sciences Industry Average Movement5.5%Market Average Movement6.4%10% most volatile stocks in IN Market9.3%10% least volatile stocks in IN Market4.1%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間の540729のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト201636Dopesh Mulakalawww.vantabio.comVanta Bioscience Limited は、その子会社とともに、インドで前臨床試験受託機関として事業を展開している。医薬品開発の前臨床段階において、試験法開発、バリデーション、不純物プロファイリング、不純物単離、特性評価、認証、評価、哺乳類および遺伝毒性学、薬物代謝、薬物動態、バイオアナリシスなど幅広いサービスを提供している。また、農薬や化学物質の物理化学試験、亜急性、亜慢性、慢性試験、トキシコキネティクス評価、CoAと用量処方分析、5バッチ分析、水中、土壌中、大気中の挙動、生物濃縮、急性6パック、発がん性、遺伝毒性、DART、環境毒性、動物代替試験などの試験サービスも提供している。さらに、スターター原料の加工、近成分・組成分析、飼料バランス・配合、放射線照射、包装・表示などの飼料配合サービス、パイロジェン試験、安定性試験、異常毒性・不純物プロファイリングなどのバッチリリース薬局方試験も提供している。さらに同社は、細胞毒性、皮膚内/粘膜刺激性、皮膚感作性、変異原性試験、急性全身毒性、移植試験などのサービスを医療機器業界に提供している。さらに、医薬品有効成分、賦形剤、抽出物、溶出物、医薬品不純物を評価するリスクアセスメントサービスや、職業暴露限度を含む1日許容暴露量または1日許容暴露量の健康ベースの暴露限度を決定する専門家サービスの提供も行っている。同社は製薬、バイオテクノロジー、化粧品、食品サプリメント、飼料添加物、農業食品、食品サプリメント業界にサービスを提供している。ヴァンタ・バイオサイエンス・リミテッドは2016年に設立され、インドのセクンダラバードに拠点を置く。もっと見るVanta Bioscience Limited 基礎のまとめVanta Bioscience の収益と売上を時価総額と比較するとどうか。540729 基礎統計学時価総額₹152.06m収益（TTM）₹1.08m売上高(TTM)₹18.16m147.4xPER（株価収益率8.8xP/Sレシオ540729 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計540729 損益計算書（TTM）収益₹18.16m売上原価-₹8.92m売上総利益₹27.09mその他の費用₹26.01m収益₹1.08m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.17グロス・マージン149.14%純利益率5.96%有利子負債／自己資本比率179.8%540729 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 11:54終値2026/07/06 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vanta Bioscience Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Kartini Hj Abdul Manaf was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹0.15 (vs ₹7.57 loss in FY 2025)Full year 2026 results: EPS: ₹0.15 (up from ₹7.57 loss in FY 2025). Revenue: ₹19.8m (flat on FY 2025). Net income: ₹1.08m (up ₹48.8m from FY 2025). Profit margin: 5.5% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • May 26Vanta Bioscience Limited to Report Second Half, 2026 Results on May 30, 2026Vanta Bioscience Limited announced that they will report second half, 2026 results on May 30, 2026
お知らせ • Nov 08Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025
お知らせ • Sep 09Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India
Reported Earnings • Aug 02Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024)Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Kartini Hj Abdul Manaf was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 02Full year 2026 earnings released: EPS: ₹0.15 (vs ₹7.57 loss in FY 2025)Full year 2026 results: EPS: ₹0.15 (up from ₹7.57 loss in FY 2025). Revenue: ₹19.8m (flat on FY 2025). Net income: ₹1.08m (up ₹48.8m from FY 2025). Profit margin: 5.5% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • May 26Vanta Bioscience Limited to Report Second Half, 2026 Results on May 30, 2026Vanta Bioscience Limited announced that they will report second half, 2026 results on May 30, 2026
お知らせ • Nov 08Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025
お知らせ • Sep 09Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India
Reported Earnings • Aug 02Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024)Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 16Vanta Bioscience Limited to Report Second Half, 2025 Results on Jul 19, 2025Vanta Bioscience Limited announced that they will report second half, 2025 results on Jul 19, 2025
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$536k). Market cap is less than US$10m (₹156.5m market cap, or US$1.83m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change).
お知らせ • May 21Vanta Bioscience Limited to Report Q4, 2025 Results on May 30, 2025Vanta Bioscience Limited announced that they will report Q4, 2025 results on May 30, 2025
New Risk • May 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹153.6m market cap, or US$1.80m).
New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹152.8m market cap, or US$1.79m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
New Risk • Nov 16New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹46m (US$543k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$543k). Market cap is less than US$10m (₹259.9m market cap, or US$3.08m).
お知らせ • Nov 12Vanta Bioscience Limited to Report First Half, 2025 Results on Nov 14, 2024Vanta Bioscience Limited announced that they will report first half, 2025 results on Nov 14, 2024
お知らせ • Sep 13Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹7.2m free cash flow). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 70% per year over the past 5 years. Market cap is less than US$10m (₹351.9m market cap, or US$4.19m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m).
Reported Earnings • Jul 25Full year 2024 earnings released: ₹3.67 loss per share (vs ₹10.27 loss in FY 2023)Full year 2024 results: ₹3.67 loss per share (improved from ₹10.27 loss in FY 2023). Revenue: ₹98.3m (up 43% from FY 2023). Net loss: ₹23.2m (loss narrowed 64% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 11Vanta Bioscience Limited to Report Second Half, 2024 Results on Jul 17, 2024Vanta Bioscience Limited announced that they will report second half, 2024 results on Jul 17, 2024
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹83m free cash flow). Earnings have declined by 76% per year over the past 5 years. Market cap is less than US$10m (₹360.0m market cap, or US$4.32m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₹103m revenue, or US$1.2m).
Board Change • Feb 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 12Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 07Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony Sikh Village, Bowenpally, Secunderabad 500009 Telangana Andhra Pradesh India
Board Change • Sep 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 12New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹70m (US$839k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Revenue is less than US$1m (₹70m revenue, or US$839k). Market cap is less than US$10m (₹371.1m market cap, or US$4.47m).
Reported Earnings • Aug 11Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022)Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 05Vanta Bioscience Limited to Report Second Half, 2023 Results on Aug 10, 2023Vanta Bioscience Limited announced that they will report second half, 2023 results on Aug 10, 2023
お知らせ • Jul 12Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that Ms. Vidisha Rathod has resigned as Company Secretary and Compliance Officer of the Company with immediate effect July 10, 2023, due to her pre-occupations and personal reasons. The Company is in the process of appointing a new Company Secretary. In the interim, Mr. Dopesh Raja Mulakala, Managing Director is being appointed as the Compliance officer of the Company.
お知らせ • May 23Vanta Bioscience Limited to Report Q4, 2023 Results on May 30, 2023Vanta Bioscience Limited announced that they will report Q4, 2023 results on May 30, 2023
お知らせ • Dec 08Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022, at 10:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad 500009 Telangana India
Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 16Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance OfficerVanta Bioscience Limited announced that the company has appointed Ms. Vidisha Rathod as company secretary and compliance officer of the company, effective September 15, 2022. Ms. Vidisha Rathod is a qualified company secretary and an associate member of ICSI. She has over 5+ years of rich experience in Secretarial matters. She has previously worked as company secretary with Public Limited Companies like Chrysalis Finance Ltd., Mimanshu Industries Ltd. and Aatash Norcontrol Limited. She has exposure of handling various secretarial and legal matters. She is being appointed as CS and Compliance Officer, effective September 15, 2022 due to the resignation of existing CS. She is not associated with any of the Directors or KMPs of the company.
お知らせ • Sep 04Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance OfficerVanta Bioscience Limited announced the resignation of Mr. Zoheb S Sayani as the Company Secretary and Compliance officer of the Company w.e.f.15.09.2022 due to his pre-occupations.
Board Change • Jul 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jun 28Insider recently bought ₹518k worth of stockOn the 21st of June, Chandra Shekar Simhadri bought around 5k shares on-market at roughly ₹98.64 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Jun 03Full year 2022 earnings released: EPS: ₹0.14 (vs ₹0.71 in FY 2021)Full year 2022 results: EPS: ₹0.14 (down from ₹0.71 in FY 2021). Revenue: ₹101.1m (flat on FY 2021). Net income: ₹882.0k (down 80% from FY 2021). Profit margin: 0.9% (down from 4.5% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹0.71 (vs ₹1.59 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹100.4m (down 29% from FY 2020). Net income: ₹4.50m (down 55% from FY 2020). Profit margin: 4.5% (down from 7.1% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 28% per year.
Is New 90 Day High Low • Mar 03New 90-day high: ₹150The company is up 7.0% from its price of ₹140 on 03 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 3.0% over the same period.
お知らせ • Jan 06Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as DirectorVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the Whole Time Director of the company with effect from the close of working hours of January 4, 2021.
お知らせ • Jan 05Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as CEOVanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the CEO of the company with effect from the close of working hours of January 04, 2021.
Is New 90 Day High Low • Dec 28New 90-day low: ₹124The company is down 31% from its price of ₹180 on 28 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 09New 90-day low: ₹134The company is down 18% from its price of ₹164 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 19% over the same period.
お知らせ • Nov 14Vanta Bioscience Limited Enters into Commercial Agreement with One of the Leading German Testing AgencyVanta Bioscience Limited announced that it has entered into a commercial agreement with one of the leading German Testing agency, wherein the Client has commissioned Vanta Bio to carry out Laboratory Testing Services in Biocompatibility and Analytics. The said agreement is valid for a period of 2 years. This is a major break through for the Company considering its decision to foray into Medical Devices vertical. This is not only an acknowledgement of the technical capabilities of Vanta Bio, but also validation of the world class services being provided by the Company. Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition. Expected to generate a revenue of INR 100 million-INR 150 million approx. over the period of 2 years.
Is New 90 Day High Low • Nov 04New 90-day low: ₹148The company is down 6.0% from its price of ₹157 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.
Is New 90 Day High Low • Sep 23New 90-day high: ₹170The company is up 32% from its price of ₹129 on 25 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 37% over the same period.
お知らせ • Jun 20Vanta Bioscience Limited to Report Fiscal Year 2020 Results on Jun 30, 2020Vanta Bioscience Limited announced that they will report fiscal year 2020 results on Jun 30, 2020
